Compare FSI & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FSI | MNOV |
|---|---|---|
| Founded | 1991 | 2000 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.8M | 66.9M |
| IPO Year | 2000 | 2004 |
| Metric | FSI | MNOV |
|---|---|---|
| Price | $5.36 | $1.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 13.0K | ★ 52.1K |
| Earning Date | 05-14-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.84% | N/A |
| EPS Growth | ★ 9.09 | N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $15,494,325.00 | $2,360,807.00 |
| Revenue This Year | $4.11 | N/A |
| Revenue Next Year | $58.09 | N/A |
| P/E Ratio | $60.44 | ★ N/A |
| Revenue Growth | N/A | ★ 194.15 |
| 52 Week Low | $3.50 | $1.17 |
| 52 Week High | $11.48 | $1.96 |
| Indicator | FSI | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | 47.64 | 48.59 |
| Support Level | $5.21 | $1.40 |
| Resistance Level | $5.47 | $1.43 |
| Average True Range (ATR) | 0.22 | 0.06 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 35.10 | 29.01 |
Flexible Solutions International Inc develops, manufactures, and markets specialty chemicals that slow the evaporation of water. Its business is organized into two segments: Energy and Water Conservation Products and Biodegradable Polymers. It offers a liquid swimming pool blanket under the WATERSAVR brand, which saves energy and water by inhibiting evaporation from the pool surface, and a chemical product called HEATSAV for use in swimming pools and spas to slow water evaporation. The firm also manufactures and markets water-soluble chemicals utilizing thermal polyaspartate biopolymers. It generates the majority of its revenues from the export of its products to international markets.
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.